Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202413514 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Ben Ma und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Thyroid Carcinoma, Anaplastic, Cyclin-Dependent Kinase 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Anaplastic thyroid cancer (ATC) is the most lethal tumor arising from thyroid follicular epithelium. Lenvatinib is an off‐label use option for ATC patients in many countries but an approved prescription in Japan. However, lenvatinib resistance is a substantial clinical challenge. Clinical ATC samples including lenvatinib‐resistant tumors are used to build patient‐derived cells and patient‐derived xenografts. High‐throughput drug screening and synergy analyses are performed to identify an effective combination partner for lenvatinib. Cellular functions are detected by cell senescence, apoptosis, cell cycle, cell viability and colony formation assays. CDK2 inhibition showed the significant synthetic lethality with lenvatinib via inhibiting G1/S transition and inducing cell senescence in ATC. High expression of CDK2 is associated with lenvatinib resistance and poor clinical outcomes of ATC patients. Lenvatinib increased protein expression of CDK2 in lenvatinib‐resistant ATC cells. Mechanistically, lenvatinib inhibited protein degradation of CDK2 via reducing CDK2's interaction with the RACK1‐FBW7 complex, which is involved in ubiquitination and subsequent proteasomal degradation of CDK2. Combination of CDK2 inhibitors in clinical trials (Dinaciclib or PF‐07104091) and lenvatinib markedly suppressed growth of xenograft tumors from the lenvatinib‐resistant patient. The findings support the combination therapy strategy of lenvatinib and CDK2 inhibitor for lenvatinib‐resistant ATC patients with high CDK2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, P. R. China.
- The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.
ORCID-Profile: Yu Wang
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Municipal Health Commission
Zitieren
APA
Ma, B., Sang, Y., Du, X., Zhang, Y., Yin, M., Xu, W., Liu, W., Lu, J., Guan, Q., Wang, Y., Liao, T., Wang, Y., Xiang, J., Shi, R., Qu, N., Ji, Q., Zhang, J., Ji, D., & Wang, Y. (2025). Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer. Advanced Science. https://doi.org/10.1002/advs.202413514
Vancouver
Ma B, Sang Y, Du X, Zhang Y, Yin M, Xu W, et al. Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer. Advanced Science. 2025. doi:10.1002/advs.202413514
BibTeX
@article{Ma2025,
author = {Ma, Ben and Sang, Youzhou and Du, Xiaoxue and Zhang, Yanzhi and Yin, Min and Xu, Weibo and Liu, Wanlin and Lu, Jiayi and Guan, Qing and Wang, Yunjun and Liao, Tian and Wang, Yuting and Xiang, Jun and Shi, Rongliang and Qu, Ning and Ji, Qinghai and Zhang, Jiwei and Ji, Dongmei and Wang, Yu},
title = {Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202413514}
}
EUVIMED